Dr. Nima Amjadi, MD

Dr. Amjadi practices at Baylor Scott and White Pflugerville Central - HOPD in Pflugerville, Texas.

Dr. Amjadi's NPI, 1114974011, was assigned on May 27, 2006. Dr. Amjadi graduated from St. George's University School of Medicine in 1997. Dr. Amjadi holds Texas license L8596.

Dr. Amjadi's primary practice is Baylor Scott and White Pflugerville Central - HOPD, at 1701 E Pflugerville Pkwy, Pflugerville, TX 78660.

Dr. Amjadi's primary practice is Baylor Scott and White Pflugerville Central - HOPD in Pflugerville, Texas. Dr. Amjadi is also affiliated with St. David's Medical Center. The medical group on file is Baylor Scott & White Temple Roney Bone and Joint Institute, Temple. Dmand AI also links Dr. Amjadi to 4 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account. Dr. Amjadi's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amjadi practices, 8 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Amjadi's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Amjadi is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Amjadi's licenses on file in 3 states: Texas, California and Arizona.

Dmand AI lists angioplasty, cardiac catheterization and leg revascularization among the conditions Dr. Amjadi treats.

CMS data shows 22,017 Medicare services from Dr. Amjadi across 39 procedure codes in 2024, for 885 Medicare patients. Medicare paid $557,321 for them.

CMS counts 885 Medicare patients who saw Dr. Amjadi in 2024. The largest group is 65 to 74, with 424 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.38, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Amjadi's median patient age at 73, with 46% women.

In 2024, Dr. Amjadi wrote 6,380 Medicare Part D claims for 950 patients. 82% of them were for generic drugs. CMS names the drug for 6,051 of them, across 57 drugs with 11 or more claims each, at $1,268,462 in total drug cost. In 2023, CMS named 5,232 claims across 55 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Amjadi for performance year 2024, reported individually. Dr. Amjadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amjadi as offering telehealth. CMS counts 13 procedures of coronary angioplasty and stenting by Dr. Amjadi, more than 35% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Amjadi in 2019. Dr. Amjadi's most frequent co-authors are Dominic J. Allocco, MD, Christopher Patrick Caputo, DO and Henry J. Chen, MD.

CMS Open Payments shows 1,569 general payments to Dr. Amjadi from 77 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 70% of the total. C. R. Bard, Inc. & Subsidiaries paid the most, $14,750.

Dmand AI lists 1 award for Dr. Amjadi.

Dr. Amjadi graduated from St. George's University School of Medicine in 1997. Dr. Amjadi is a member of ACC.

Dr. Amjadi is in network with 22 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.